Carna BiosciencesCarna Biosciences, Inc.4572東証グロース医薬品FY ending Dec 2025, consolidated, J-GAAP
Revenue by business segment, and the profit each one keeps.
Geographic revenue reported in annual filings
No geographic revenue breakdown was disclosed.
※ Segment figures include inter-segment sales and do not sum to the company total
X-axis: segment revenue CAGR. Y-axis: latest operating margin. Bubble size: revenue.
Margin data is available for 1 businesses. At least two are needed for comparison.
| Segment | Revenue CAGR | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|---|
| Drug discovery support business | -11.7%5y | 89032.5% | 1,10141.1% | 91824.6% | 636-5.4% | 579-8.8% |
| Drug discovery business | — | 1,128-72.7% | 286-602.2% | 708-189.7% | — | — |
Top: revenue. Bottom: operating margin.
EDINET (FSA Japan)
有価証券報告書－第23期(2025/01/01－2025/12/31)
EDINET (FSA Japan)
有価証券報告書－第22期(2024/01/01－2024/12/31)
EDINET (FSA Japan)
有価証券報告書－第21期(2023/01/01－2023/12/31)
EDINET (FSA Japan)
有価証券報告書－第20期(2022/01/01－2022/12/31)
EDINET (FSA Japan)
有価証券報告書－第19期(令和3年1月1日－令和3年12月31日)
EDINET (FSA Japan)
有価証券報告書－第18期(令和2年1月1日－令和2年12月31日)
Extracted from XBRL: 40 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.